Aevi Genomic Medicine, Inc. (NASDAQ:GNMX)‘s stock had its “hold” rating reissued by analysts at Jefferies Group LLC in a report released on Monday. They currently have a $1.50 price target on the biotechnology company’s stock. Jefferies Group LLC’s price objective points to a potential upside of 27.12% from the company’s current price.

Other analysts have also recently issued reports about the company. UBS AG reissued a “positive” rating on shares of Aevi Genomic Medicine in a research note on Wednesday, May 10th. ValuEngine cut Aevi Genomic Medicine from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd.

Shares of Aevi Genomic Medicine (NASDAQ:GNMX) opened at 1.18 on Monday. Aevi Genomic Medicine has a 12-month low of $0.98 and a 12-month high of $6.89. The company’s 50 day moving average is $1.30 and its 200 day moving average is $2.56. The firm’s market capitalization is $43.79 million.

Aevi Genomic Medicine (NASDAQ:GNMX) last posted its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by $0.02. On average, analysts forecast that Aevi Genomic Medicine will post ($1.08) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) Rating Reiterated by Jefferies Group LLC” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/08/07/aevi-genomic-medicine-inc-nasdaqgnmx-rating-reiterated-by-jefferies-group-llc.html.

Hedge funds have recently bought and sold shares of the company. Birchview Capital LP boosted its stake in Aevi Genomic Medicine by 41.7% in the first quarter. Birchview Capital LP now owns 68,000 shares of the biotechnology company’s stock worth $126,000 after buying an additional 20,000 shares during the last quarter. LMR Partners LLP acquired a new position in shares of Aevi Genomic Medicine during the second quarter valued at $149,000. TIAA CREF Investment Management LLC boosted its position in shares of Aevi Genomic Medicine by 16.7% in the first quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock valued at $182,000 after buying an additional 13,966 shares in the last quarter. Teachers Advisors LLC acquired a new position in shares of Aevi Genomic Medicine during the fourth quarter valued at $204,000. Finally, State Street Corp boosted its position in shares of Aevi Genomic Medicine by 15.4% in the fourth quarter. State Street Corp now owns 345,698 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 46,149 shares in the last quarter. 27.97% of the stock is owned by institutional investors and hedge funds.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohnÂ’s disease.

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.